LIXTE Biotechnology Joins Russell Microcap Index

Written by Emily J. Thompson, Senior Investment Analyst

Source: Newsfilter

Updated: Jun 26 2026

0mins

LIXT-6.38%

Explore Agentic TradingLet AI Trade for You

Source: Newsfilter

Inclusion in Russell Microcap: LIXTE Biotechnology officially joins the Russell Microcap Index after the market close on June 26, 2026, marking a significant milestone that is expected to enhance its visibility among institutional investors.
Successful Strategic Transformation: Under new leadership, LIXTE has successfully transformed into a platform focused on AI energy infrastructure equipment and services, aiming to meet the rapidly growing power and infrastructure demands, thereby enhancing shareholder value.
Increased Market Recognition: Membership in the Russell Microcap Index will attract more attention from investment products and funds that benchmark against Russell indexes, further expanding the company's market influence.
Growing Industry Demand: LIXTE's transformation comes at a pivotal time as demand for reliable and efficient energy infrastructure solutions accelerates alongside the expansion of AI and hyperscale data centers.

Trade with 70% Backtested Accuracy

Stop guessing "Should I Buy LIXT?" and start using high-conviction signals backed by rigorous historical data.

Analyst Views on LIXT

About LIXT

Lixte Biotechnology Holdings, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on identifying new targets for cancer drug development and developing and commercializing cancer therapies. The Company’s product pipeline is primarily focused on inhibitors of protein phosphatase 2A, which is used to enhance cytotoxic agents, radiation, immune checkpoint blockers and other cancer therapies. The Company’s inhibitors of protein phosphatases have significant therapeutic potential for a broad range of cancers. It is focused on the clinical development of a specific protein phosphatase inhibitor, LB-100. In addition, lead compounds of the LB-100 series have anti-cancer activity in animal models of glioblastoma multiforme, neuroblastoma, and medulloblastoma, all cancers of neural tissue. Its subsidiary, Liora Technologies Europe Ltd., offers electronically controlled proton therapy systems for treating tumors in various types of cancers.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

NOMAD's Name Change Reflects Strategic Transition

1 day agoNewsfilter

Name Change: NOMAD Power Solutions, Inc., formerly LIXTE Biotechnology Holdings, Inc., completed its name change on July 6, 2026, and began trading under the new ticker NMAD on Nasdaq, marking a strategic transition into the AI energy infrastructure equipment and services sector.
Acquisition Impact: This name change is closely tied to the acquisition of NOMAD Transportable Power Systems, a leader in meeting the rapidly growing power demands of AI and hyperscale data centers, which is expected to significantly enhance NOMAD's market share and revenue growth.
Market Opportunity: NOMAD's mobile battery energy storage systems provide instantaneous power to grids or facilities, bypassing the months of construction typically required for traditional fixed installations, which is anticipated to greatly enhance the company's competitiveness in the rapidly evolving AI energy market.
Strategic Focus: The company has decided to cease operations in its legacy life sciences market and is exploring options for the sale or merger of those assets, allowing it to concentrate on AI-driven energy infrastructure solutions, which is expected to create long-term value for shareholders.

NOMAD Power Solutions Transitions to NMAD Ticker Amid AI Energy Shift

1 day agoNewsfilter

Corporate Name Change: NOMAD Power Solutions, Inc., formerly known as LIXTE Biotechnology Holdings, Inc., has completed its name change and began trading under the new ticker NMAD on Nasdaq as of July 6, 2026, marking its transition into the AI energy infrastructure equipment and services sector.
Market Opportunity: The company is entering a multi-billion dollar rapidly growing market focused on meeting the power and infrastructure needs of artificial intelligence, cloud computing, and hyperscale data center operators, which is expected to create long-term shareholder value.
Innovative Product: NOMAD has introduced a mobile, truck-transportable battery energy storage system that provides instantaneous power to grids or facilities, bypassing the months of construction typically required for traditional fixed installations, significantly enhancing market responsiveness.
Strategic Positioning: This transformation represents a major corporate reinvention in the company's history, reflecting its strategic intent to seek competitive advantages in the rapidly evolving AI energy market by offering flexible energy solutions to meet the growing demand for power.

NOMAD Power Solutions Completes Corporate Name Change to NMAD

1 day agoPRnewswire

Successful Transformation: NOMAD Power Solutions, Inc., formerly known as LIXTE Biotechnology Holdings, Inc., has completed its name change and began trading under the new Nasdaq ticker NMAD on July 6, 2026, marking a successful transition into the AI energy infrastructure sector, which is expected to create long-term shareholder value.
Surging Market Demand: With rapidly increasing power demands from data centers, NOMAD's mobile battery energy storage systems can be deployed quickly to provide instantaneous power, addressing the urgent need for flexible and efficient energy solutions in a multi-billion dollar market.
Innovative Product Advantage: NOMAD's products are truck-transportable and can connect to the grid in minutes, bypassing the months of construction typically required for traditional fixed installations, which gives it a competitive edge, particularly in the AI and cloud computing sectors.
Strategic Market Positioning: The company focuses on meeting the infrastructure needs of AI, cloud computing, and hyperscale data centers, positioning itself to benefit from the global expansion of AI and seize opportunities in this rapidly growing market, driving future business growth.

LIXTE Merges with NOMAD to Enter Multi-Billion-Dollar Battery Storage Market

5 days agoNewsfilter

Merger Completion: LIXTE has successfully merged with NOMAD Transportable Power Systems, issuing 2,992,041 shares of common stock and 50,366.07 shares of newly authorized Series D preferred stock to NOMAD shareholders, marking its entry into the multi-billion-dollar mobile battery storage market.
Corporate Name Change: Following the merger, LIXTE will change its name to NOMAD Power Solutions effective July 3, 2026, and its trading symbol to 'NMAD' on July 6, enhancing brand recognition and market positioning in emerging sectors.
Growing Market Demand: NOMAD is actively engaged in over 30 utility and infrastructure projects across North America in 2026, underscoring the essential role of deployable battery energy storage systems in modern grids to meet increasing power infrastructure demands.
Strategic Transformation: This merger transitions LIXTE from a focus on cancer therapies to an energy equipment platform targeting AI and cloud computing infrastructure, with expectations of sustainable growth driven by the rapidly increasing demand for reliable energy solutions.

LIXTE Biotechnology to Join Russell Microcap Index

Jun 26 2026seekingalpha

Inclusion in Russell Index: LIXTE Biotechnology announced its inclusion in the Russell Microcap Index effective after the close of U.S. equity markets on June 26, 2026, which is expected to enhance the company's visibility among investors and attract more institutional interest.
Effective Date: The reconstituted indexes will take effect at the opening of trading on June 29, 2026, providing the company ample time to optimize its market strategies in anticipation of the upcoming changes.
Acquisition Deal: LIXTE Biotechnology has signed a deal to acquire 100% of NOMAD to meet grid demand, a strategic acquisition that will enhance the company's competitive position and expand its business scope.
Financing Activity: The company has priced a $16.6 million registered direct offering, which will provide necessary funding for future expansions and acquisitions, further driving the company's growth potential.